Recent News
Today, our research tools and technologies are transforming stem cell-based research. With the great promise of stem cell therapeutics to treat, and possibly cure, a broad range of human diseases. At ESI BIO, with the support of our parent company BioTime, Inc., we focus on developing research reagents that are translatable to the clinical. Follow our progress as we work to make this exciting and unique vision a reality.
December 15, 2014
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
April 23, 2014
BioTime Division ESI BIO Launches New Responsive Design Website to the Scientific Community
October 28, 2013
BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products - Appoints Jeffrey Janus as CEO of ES Cell International Pte Ltd.
May 3, 2010
Acquisition to Accelerate Development of Research and Therapeutic Products
